First Affirmative Financial Network owns $256,000 in Bristol-Myers Squibb (NYSE:BMY)

First Affirmative Financial Network boosted its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 19.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,718 shares of the biopharmaceutical company’s stock after acquiring an additional 767 shares during the period. First Affirmative Financial Network’s holdings in Bristol-Myers Squibb were worth $256,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $1,560,524,000. Primecap Management Co. CA boosted its holdings in shares of Bristol-Myers Squibb by 14.6% in the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company’s stock worth $1,207,549,000 after acquiring an additional 2,998,228 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Bristol-Myers Squibb by 7.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 16,959,807 shares of the biopharmaceutical company’s stock valued at $870,198,000 after buying an additional 1,246,066 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Bristol-Myers Squibb by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 11,361,717 shares of the biopharmaceutical company’s stock valued at $582,970,000 after purchasing an additional 134,815 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Bristol-Myers Squibb by 36.7% in the fourth quarter. Franklin Resources Inc. now owns 9,357,199 shares of the biopharmaceutical company’s stock valued at $480,118,000 after buying an additional 2,510,134 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s shares.

Bristol-Myers Squibb Price Performance

Shares of NYSE:BMY opened at $41.93 on Friday. The stock has a market cap of $85.00 billion, a PE ratio of -13.53, a PEG ratio of 13.89 and a beta of 0.43. The company’s fifty day moving average is $43.60 and its 200 day moving average is $48.43. Bristol-Myers Squibb has a 52-week low of $39.63 and a 52-week high of $65.85. The company has a quick ratio of 0.99, a current ratio of 1.11, and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue increased by 4.7% year-on-year. In the same quarter last year, the firm earned $2.05 EPS. research analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a $0.60 dividend. This represents a dividend of $2.40 on an annualized basis and a yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Analysts on Wall Street are forecasting an increase

BMY has been the subject of several analyst reports. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th . Barclays cut their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $60.00, according to MarketBeat .

Check out our latest analysis of Bristol-Myers Squibb

Bristol-Myers Squibb Company Profile

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See also

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.